Maiva Pharma inaugurates new sterile injectables manufacturing facility in Tamil NaduIllustrative image – not actual.

Maiva Pharma, a global contract manufacturing and contract development organisation specialising in sterile injectables, has inaugurated its new manufacturing facility at Shoolagiri in Tamil Nadu.

Spread across a 22-acre site, the facility has been designed with advanced manufacturing technologies, flexible production systems, and world-class quality infrastructure to meet evolving global market requirements. Upon full development, it will house six production lines capable of manufacturing a wide range of sterile injectable dosage forms, including vials, pre-filled syringes, cartridges, suspensions, and lyophilized products. As part of Phase 1, the company has already commissioned three lines, including a high-speed vial filling line, a combined pre-filled syringe and cartridge line, and a lyophilization line, supported by advanced chemical and microbiology laboratories for in-house quality testing.

The facility features isolator-based manufacturing systems that enhance sterility assurance, operational efficiency, and flexibility while ensuring compliance with global regulatory standards. The expansion significantly strengthens Maiva Pharma’s ability to support end-to-end product development and commercial manufacturing, reinforcing its role as a trusted global partner in delivering high-quality sterile injectable therapies.

← All latest storiesBack to top →